vitamin K antagonist

Advertisement
Patrick DalyAtrial Fibrillation | April 23, 2023
In a study in the European Stroke Journal, researchers compared once-daily direct oral anticoagulant (DOAC) use, ...
Patrick DalyAtrial Fibrillation | September 6, 2022
In a post hoc analysis of the AUGUSTUS trial, researchers evaluated apixaban or vitamin K antagonists (VKA) and aspirin ...
Patrick DalyAtrial Fibrillation | April 7, 2023
In a meta-analysis, published in Catheterization and Cardiovascular Interventions, researchers concluded outcomes with ...
Patrick DalyAtrial Fibrillation | April 23, 2023
Oral anticoagulation (OAC) therapy is used for stroke prevention in patients with atrial fibrillation (AFib), but does ...
DocWire News EditorsCardiology | February 18, 2022
NOACs May Be Better Choice for Patients With A-Fib and DM ...
DocWire News EditorsAtrial Fibrillation | April 23, 2023
Diabetes mellitus (DM) is a common comorbidity in patients with atrial fibrillation (AF) and is associated with an ...
Rob DillardAtrial Fibrillation | November 1, 2021
Recent observational studies have compared the safety and efficacy profiles between non-vitamin K antagonist oral ...
DocWire News EditorsACC 2019 Conference | July 14, 2023
The combination of apixaban and clopidogrel was associated with a reduced risk for bleeding and hospitalization in ...
DocWire News EditorsAtrial Fibrillation | April 7, 2023
Warfarin and non-vitamin K oral anticoagulants both showed clinical benefit in very elderly atrial fibrillation (AFib) ...
Advertisement